2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1645

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Abstract Number: 1834

Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?
Abstract Number: 2639

Towards Patient-Centeredness of the Treat-to-Target Paradigm: Development of a Framework for Evaluation of Patients with Rheumatoid Arthritis in the Setting of Patient-Physician Discordance
Abstract Number: 1529

Trabecular Bone Score in Early Rheumatoid Arthritis
Abstract Number: 351

Trabecular Bone Score Is Severely Affected in Male Patients with Chronic Obstructive Pulmonary Disease
Abstract Number: 2700

Trabecular Thinning in Metacarpophalangeal Joints of Anticitrullinated Peptide Antibody Positive Patients with Arthralgia
Abstract Number: 2719

Track Along: Monocytes Follow Fibroblast-like Synoviocyte Network for Movement and Rest within the Synovial Tissue
Abstract Number: 1543

Traditional Risk Score Underestimates the Cardiovascular Risk in Rheumatoid Arthritis Patients
Abstract Number: 2666

Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort
Abstract Number: 1159

Transcription Factor SOX5 Promotes Rheumatoid Arthritis Synovial Fibroblast Migration and Invasion By Regulating MMP9 Expression
Abstract Number: 799

Transcriptional Profiling of Cutaneous Lupus Reveals Pronounced Changes in Keratinocyte and Myeloid Lineage Expressed Genes and Demonstrates Uniquely Regulated Interferon Pathways Between Rash Subtypes
Abstract Number: 2807

Transcriptome Profiling of Synovium from Patients with Psoriatic Arthritis or Osteoarthritis Using RNA Sequencing Provides Insights into Disease Mechanisms Involved in Heterotopic Ossification with Potential Therapeutic Implications
Abstract Number: 1661

Translational Data and Phase 1 Study Results of a New Monoclonal Antibody Targeting Toll like Receptor 4 (TLR4) Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine
Abstract Number: 1129

Transthyretin Deposition Accelerates the Development of Experimental Osteoarthritis in Mice
Abstract Number: 1662

Treat to Target of Remission Is Effective but Not All Patients Are Always in Remission

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].